Aytu Biopharma (AYTU) Depreciation & Amortization (CF) (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Depreciation & Amortization (CF) data on file, last reported at $1.1 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $1.1 million, down 12.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.3 million (down 21.9% YoY), and the FY2025 annual result was $5.4 million, down 20.04% from the prior year.
• Depreciation & Amortization (CF) advanced to $1.1 million in Q1 2026 per AYTU's latest filing, from $885000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $2.6 million in Q1 2022 and troughed at $803000.0 in Q3 2025.
• A 5-year average of $1.7 million and a median of $1.6 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2023 and 2024: Depreciation & Amortization (CF) declined 3.09% in 2023, then tumbled 40.18% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $2.2 million in 2022, then decreased by 18.81% to $1.8 million in 2023, then declined by 27.86% to $1.3 million in 2024, then plunged by 31.5% to $885000.0 in 2025, then grew by 26.67% to $1.1 million in 2026.
• Business Quant data shows AYTU's Depreciation & Amortization (CF) at $1.1 million in Q1 2026, $885000.0 in Q4 2025, and $803000.0 in Q3 2025.